Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SNCA | P37840 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11403497 | 0.83 | ALOX15 (0.48) | ALOX15ESR1SLC22A12HDAC6MAPT | |
| SCHEMBL29748630 | 0.82 | ALDH1A1 (0.53) | ALOX15ESR1SLC22A12HDAC6MAPT | |
| SCHEMBL7683262 | 0.82 | MAPT (0.40) | HDAC6MAPTCA1CA2TTR | |
| SCHEMBL30436340 | 0.80 | CA12 (0.64) | ALOX15ESR1MAPTSNCAKDM4E | |
| SCHEMBL312791 | 0.80 | CA12 (0.64) | ALOX15ESR1MAPTSNCAKDM4E | |
| SCHEMBL10882023 | 0.80 | ALDH1A1 (0.38) | MAPTCA1CA2TTRCES2 | |
| SCHEMBL8484882 | 0.79 | CA12 (0.62) | HDAC6MAPTSNCAKDM4ECA12 | |
| SCHEMBL2268166 | 0.78 | ALDH1A1 (0.37) | ALOX15MAPTCA1CA2L3MBTL1 | |
| SCHEMBL2964948 | 0.78 | TSHR (0.43) | MAPTKDM4EALDH1A1 | |
| SCHEMBL985272 | 0.78 | PKM (0.55) | ALOX15ESR1MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206355-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and optically anisotropic body | LG CHEM, LTD. (KR) | 2015-12-08 | — | — | US | disclosed |
| US-9206355-B2 | Polymerizable liquid crystal compound, polymerizable liquid crystal composition, and optically anisotropic body | LG CHEM, LTD. (KR) | 2015-12-08 | — | — | US | disclosed |
| US-20150115199-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND OPTICALLY ANISOTROPIC BODY | LG CHEM, LTD. (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20150115199-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, AND OPTICALLY ANISOTROPIC BODY | LG CHEM, LTD. (KR) | 2015-04-30 | — | — | US | disclosed |
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | JAPAN TOBACCO INC. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | JAPAN TOBACCO INC. (JP) | 2008-03-13 | — | — | US | disclosed |
| EP-1820515-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007075896-A2 | HETEROCYCLIC CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305169-A1 | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds | NOD1, NLRP3, SLC10A1 | ALOX15 2153/4885ESR1 2898/4885SLC22A12 446/4885 |
| US-20070010670-A1 | Nitrogen-containing fused ring compounds and use thereof | NUDT1, NOD1, SLC28A1 | ALOX15 1250/4885ESR1 3109/4885SLC22A12 260/4885 |
| US-20080064871-A1 | Production Method of Nitrogen-Containing Fused Ring Compounds | NOD1, XDH, URB2 | ALOX15 1106/4885ESR1 4648/4885SLC22A12 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.